| 1 |
31789418 | Homoharringtonine promotes BCR‑ABL degradation through the p62‑mediated autophagy pathway. | 2020 Jan |
2 |
| 2 |
27268912 | Protein synthesis inhibitors of natural origin for CML therapy: semisynthetic homoharringtonine (Omacetaxine mepesuccinate). | 2016 |
1 |
| 3 |
24516334 | Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia. | 2014 |
1 |
| 4 |
24159169 | Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells. | 2013 Oct 24 |
1 |
| 5 |
23187745 | Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia. | 2012 Oct |
2 |
| 6 |
20673586 | Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients. | 2011 Jan |
1 |
| 7 |
21294709 | Omacetaxine as an anticancer therapeutic: what is old is new again. | 2011 |
1 |
| 8 |
21030353 | The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge. | 2010 Oct |
2 |
| 9 |
18028486 | ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. | 2008 Jan |
1 |
| 10 |
17881650 | Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. | 2007 Oct 1 |
1 |